Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.11, $0.15 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $100.8 million versus the consensus estimate of $111.57 million.

2017 FORECASTFull Year 2017 Forecast:

The company recently announced two strategic acquisitions, which are anticipated to close before the end of the year. Once both transactions have closed, the company will be in a better position to update 2017 guidance, if appropriate. Therefore, at this time for the full year of 2017 the company is reaffirming its financial forecast, specifically:

• Total revenue of $500 to $530 million, including BioThrax sales of $265 to $280 million
• GAAP net income of $60 to $70 million
• Adjusted net income of $70 to $80 million (3)
• EBITDA of $135 to $145 million (3)

(3) See “Reconciliation of Net Income to Adjusted Net Income and EBITDA” for a definition of terms and a reconciliation table.

3Q 2017 Forecast:

• Total revenue of $115 to $130 million

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.